Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Eccles

Showing results (211-220 of 240) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugsMike I Walton, Paul D Eve, Angela Hayes, et al.
Cancer Research|August 15, 2008
CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cellsDavid Krige, Lindsey A Needham, Lindsay J Bawden, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Transient MYC Mimicking the Exercise Response Orchestrates Multifaceted Skeletal Muscle AdaptationsRonald G Jones, Pieter J Koopmans, Nathan Serrano, et al.
Communications Biology|May 18, 2019
ALK2 inhibitors display beneficial effects in preclinical models of <i>ACVR1</i> mutant diffuse intrinsic pontine gliomaDiana Carvalho, Kathryn R Taylor, Nagore Gene Olaciregui, et al.
Molecular Cancer Therapeutics|July 9, 2009
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Florence I Raynaud, Suzanne A Eccles, Sonal Patel, et al.
F1000Research|February 3, 2016
MinION Analysis and Reference Consortium: Phase 1 data release and analysisCamilla L C Ip, Matthew Loose, John R Tyson, et al.
Cancer Cell|July 14, 2012
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastomaTeeara Berry, William Luther, Namrata Bhatnagar, et al.
Journal of Medicinal Chemistry|April 5, 2023
HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other MalignanciesA Elisa Pasqua, Swee Y Sharp, Nicola E A Chessum, et al.
British Journal of Cancer|March 24, 2017
Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacyAmir Faisal, Grace W Y Mak, Mark D Gurden, et al.
Oncotarget|August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaMike I Walton, Paul D Eve, Angela Hayes, et al.
Pageof 24

Showing results (211-220 of 240) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugsMike I Walton, Paul D Eve, Angela Hayes, et al.
Cancer Research|August 15, 2008
CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cellsDavid Krige, Lindsey A Needham, Lindsay J Bawden, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Transient MYC Mimicking the Exercise Response Orchestrates Multifaceted Skeletal Muscle AdaptationsRonald G Jones, Pieter J Koopmans, Nathan Serrano, et al.
Communications Biology|May 18, 2019
ALK2 inhibitors display beneficial effects in preclinical models of <i>ACVR1</i> mutant diffuse intrinsic pontine gliomaDiana Carvalho, Kathryn R Taylor, Nagore Gene Olaciregui, et al.
Molecular Cancer Therapeutics|July 9, 2009
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Florence I Raynaud, Suzanne A Eccles, Sonal Patel, et al.
F1000Research|February 3, 2016
MinION Analysis and Reference Consortium: Phase 1 data release and analysisCamilla L C Ip, Matthew Loose, John R Tyson, et al.
Cancer Cell|July 14, 2012
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastomaTeeara Berry, William Luther, Namrata Bhatnagar, et al.
Journal of Medicinal Chemistry|April 5, 2023
HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other MalignanciesA Elisa Pasqua, Swee Y Sharp, Nicola E A Chessum, et al.
British Journal of Cancer|March 24, 2017
Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacyAmir Faisal, Grace W Y Mak, Mark D Gurden, et al.
Oncotarget|August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaMike I Walton, Paul D Eve, Angela Hayes, et al.
Pageof 24